AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01881893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACHD-CARE Program
Description: The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.
Study NCT03139825 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exploring the feasibility of learning during cognitive tasks (EEG-NIRS)
Description: Exploring the feasibility of the study in its aspects of recruitment and tolerability of tasks and acquisition of electrical and hemodynamic data that can be used during cognitive tasks
Study NCT02946593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroll Safe outdoor fall prevention program
Description: The structure of the program will model the evidenced-based Lifestyle Re-Design program (Clark et al., 2012). Session 1, 2, 4 \& 5 will include a brief didactic presentation about outdoor fall risks and strategy use from the group leader. This will be followed by group discussion/problem solving related to addressing risks. Identified strategies will be recorded on a wipe board and transcribed for group members in order to create handouts. Each 90 minute session will end with action planning, where participants will write down behavioral changes they will implement in the coming week. Session 3 and 6, also 90 minutes, will include outdoor mobility training and practice using strategies discussed in previous sessions. Training sessions will be led by the PI and an assistant. The final session will be a review of risks, strategy use, and reinforcement of behavioral changes in participant's action plans.
Study NCT02004093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
Study NCT04346381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Intravenous (IV) camrelizumab on Day 1 of each cycle
Study NCT02946593 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outdoor fall prevention brochure
Description: The control group participants will be given a written brochure on tips for preventing outdoor falls.
Study NCT04346381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: famitinib po qd
Study NCT00414596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRX9000™
Description: Device is designed to apply spinal decompressive forces.
Study NCT04030871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule Dome G-Tube
Description: Feeding replacement tubes with two different FDA approved devices in forty subjects
Study NCT04030871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Bolus feeding tube
Description: Feeding replacement tubes with two different FDA approved devices in forty subjects
Study NCT04356911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO (Negative Control)
Description: The group received in-office bleaching. A 45-minute application of 35% hydrogen peroxide gel (Whiteness HP, FGM, Joinville, SC) was carried. After whitening therapy, a water-soluble placebo gel (KY®, Johnson \& Johnson, SP, Brazil) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the placebo gel for 20 seconds in each tooth surface. After washing the placebo gel, the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of low-level laser therapy (LLLT).~This protocol was performed in 3 sessions, with an interval of seven days between them.
Study NCT04356911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FBM
Description: This group received photobimodulation with low level laser therapy (LLLT) of infrared spectrum with a wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), at two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. The laser was applied in 3 sessions with a time interval of seven days between them.
Study NCT04356911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESTRÔNCIO
Description: After whitening therapy, a toothpaste with 10% strontium chloride (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. The desensitizer therapy was realized in 3 sessions with a time interval of seven days between them.
Study NCT04356911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FBM+ESTRÔNCIO
Description: After whitening therapy, a 10% strontium chloride toothpaste (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of whitened teeth with the help of a Microbrush applicator applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. After washing the desensitizer, the photobimodulation was realized with Low Level Laser Therapy (LLLT) of infrared spectrum with wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), in two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. This protocol was performed in 3 sessions, with an interval of seven days between them.
Study NCT03519867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8616
Description: MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion. Doses are based on actual body weight.
Study NCT03519867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zemuron®
Description: Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs. If needed, a maintenance dose of 0.15 mg/kg will be given. Doses are based on actual body weight.
Study NCT05354076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride liposome injection
Description: According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.(For breast cancer patients: liposomal doxorubicin 35mg/m2 q3w)
Study NCT02205411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartAssist 5® VAD System
Description: The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.
Study NCT02205411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control VAD
Description: The HeartMate II® VAD or HVAD®
Study NCT01846624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT01846624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Given PO
Study NCT05522816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX01 0.01% (0.1 mg/g)
Description: Stage 1: 6 patients (KX01 0.01% \[0.1 mg/g\])
Study NCT05522816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05522816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX01 0.1% (1.0 mg/g)
Description: Stage 2: 6 patients (KX01 0.1% \[1.0 mg/g\])
Study NCT05522816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX01 1% (10 mg/g) for 5 days
Description: Stage 3: 6 patients (KX01 1% \[10 mg/g\]) for 5 days
Study NCT05522816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
Description: Stage 4: 6 patients (KX01 1% \[10 mg/g\])for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
Study NCT00895141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated Fat Diet
Description: Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
Study NCT00895141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated Fat Diet
Description: Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
Study NCT03976791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enlarged internal incision
Description: enlarging the internal incision about 0.4mm
Study NCT03976791 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: regular 2.2mm incision
Description: 2.2mm microincision coaxial phacoemulsification
Study NCT03687814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet/PEG 3350
Description: Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
Study NCT03687814 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham diet/PEG 3350
Description: Subjects will follow a sham diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
Study NCT04009317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3139
Description: a multi-target protein kinase inhibitor.
Study NCT04009317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: a multi-target protein kinase inhibitor.
Study NCT02022345 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Study NCT00606606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Study NCT02722993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Study NCT02722993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03743181 — intervention group
Intervention type: OTHER
Intervention: pharmaceutical care services
Description: detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life
Study NCT02986360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vidscrip educational video
Description: Vidscrip educational video provide to women
Study NCT05035381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen
Description: MSI-H colorectal cancer, recurrence and metastasis within 1 year after surgery, or failure of first-line oxaliplatin and fluorouracil chemotherapy for advanced colorectal cancer, PD-1 inhibitors combined with bevacizumab and FOLFIRI regimen
Study NCT02900378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 (Sacubitril/Valsartan)
Description: LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
Study NCT02900378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCZ696 (Sacubitril/Valsartan)
Description: Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
Study NCT03571529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG-driven exoskeleton hand robot
Description: Primary Outcome Measurement:~1. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale At the beginning of each robotic treatment session, superficial EMG recording will be taken at relax position ( without muscle contraction) and then during maximal voluntary isometric contraction (MVC) after the patient's hand is placed in the exoskeleton. For both, EMG recording is performed for 7 seconds and Root Mean Square (RMS) is calculated from this record.
Study NCT03571529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Primary Outcome Measurement:~1. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale
Study NCT02366975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel 2%
Description: testosterone gel 2% (50mg/die).
Study NCT02366975 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo gel
Study NCT02098642 — intervention group
Intervention type: OTHER
Intervention: MIRT
Description: A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.
Study NCT02098642 — intervention group
Intervention type: OTHER
Intervention: Mobilization of the metatarsophalangeal joint of the hallux
Description: MIRT and mobilization of the metatarsophalangeal joint of the hallux
Study NCT04468620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistive Soft Skills & Employment Training (ASSET)
Description: The ASSET curriculum covers six key social skill areas: (a) Communication; (b) Networking; (c) Attitude \& Enthusiasm; (d) Teamwork; (e) Problem Solving \& Critical Thinking; and (f) Professionalism, as well as new content added based on our pilot findings (Mental Health; Stress Management and Self-Advocacy; and Awareness of Self \& Others). The schedule includes two sessions for Communication and Professionalism, and a graduation session; thus, bringing the total number of sessions to 13. The structural elements of the training format include didactic lecture, experiential activities, group discussions, role-plays, performance feedback,and weekly take-home assignments. A key element is a social hour following each 90-minute session, in which participants practice learned skills while sharing a meal.
Study NCT04000035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health and work environment information and processes
Description: see arm/group description
Study NCT04000035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health and work environment information and processes
Description: see arm/group description
Study NCT03387475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: iron chelation
Study NCT03446391 — intervention group
Intervention type: PROCEDURE
Intervention: Kinematic alignment
Description: The principle for kinematically aligning the femoral component is to remove the correct amount of bone and cartilage from the distal and posterior femur after accounting for wear and saw blade kerf, so that the total thickness of the missing and removed tissue matches the thickness of the femoral component.
Study NCT03446391 — intervention group
Intervention type: PROCEDURE
Intervention: Mechanical alignment
Description: Classic mechanical alignment (MA) in total knee arthroplasty (TKA) is meant to co-align the prosthetic components to the mechanical axes of the femur and tibia and restore neutral overall limb alignment
Study NCT03446391 — intervention group
Intervention type: DEVICE
Intervention: GMK Sphere®
Description: The GMK Sphere® is a total knee prosthesis . The design of the GMK Sphere® is characterized by a spherical medial femoral condyle and an asymmetrical fixed tibial UHMWPE polyethylene insert with a concave spherical medial compartment.
Study NCT04304651 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Limited cancer screening
Description: The limited cancer screening will include: 1) a complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin); and 4) chest X-ray.~In women, a breast examination, Pap smear/pelvic examination (if \< 70 years old and previously sexually active) and mammogram will be performed, if not conducted in last year.~In men, similarly, prostate examination and PSA testing will be performed, if not conducted in the last year.~All patients will undergo colon cancer screening as per local practice.
Study NCT04304651 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Limited cancer screening + FDG PET/CT
Description: The limited cancer screening (as described above) in combination with a FDG PET/CT.
Study NCT03398525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: usual care following local standard operational procedures
Study NCT03398525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care following local standard operational procedures
Study NCT03398525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musical intervention
Description: Musical intervention using a marketed music program validated for music therapy
Study NCT02824731 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation with protons
Study NCT02824731 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation with photons
Study NCT06119009 — intervention group
Intervention type: OTHER
Intervention: non interventions
Study NCT04093427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: softSTOPP
Description: Non-invasive ventilation device setting in prismaVENT 30 device enabling an inverse pressure ramp after therapy end
Study NCT04692454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modern acupuncture
Description: use the scalp and ear acupuncture methods to identify diseases and checkpoints and apply them to regulate the immune function of patients with gastroenterological cancers.
Study NCT02416752 — intervention group
Intervention type: DRUG
Intervention: Remifentanil
Description: The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group
Study NCT02416752 — intervention group
Intervention type: DRUG
Intervention: choice of intra-operative opioids were left to the discretion of anesthesiologist
Study NCT00605592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic Islets of Langerhans Cell Transplant
Description: Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
Study NCT04165993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and KN026
Description: 30 mg/kg Q3W KN026 75 mg/m2 docetaxol
Study NCT04165993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 monotherapy
Description: 30 mg/kg Q3W KN026
Study NCT02900378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril was available in 2.5 mg, 5 mg and 10 mg film-coated tablets
Study NCT02900378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Enalapril
Description: Placebo of Enalapril was available to match 2.5 mg, 5 mg and 10 mg film-coated tablets
Study NCT00445913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diabetes-suppressive dendritic cell vaccine
Description: The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
Study NCT04165993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 combination
Description: 30 mg/kg Q3W KN026 5 mg/kg Q3W KN046
Study NCT00376584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A
Study NCT00376584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-0524A
Study NCT00376584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ER Niacin
Study NCT00376584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00376584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo